Comparison of Intramuscular and Intravenous ACTH Stimulation Test in Normal Volunteers

NCT ID: NCT03752190

Last Updated: 2019-05-10

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE4
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-07-31
• Study Completion Date: 2020-12-31

Brief Summary

Cosyntropin (synthetic ACTH) stimulation test is considered the optimal test for diagnosis of primary and long-standing secondary adrenal insufficiency.

The standard cosyntropin stimulation test is performed by administering 250 µg cosyntropin intravenously. Serum cortisol is measured before, and at 30 and 60 minutes after the bolus injection. Peak cortisol levels below 500 nmol/L (18.1 µg/dL) at 30 or 60 minutes after cosyntropin administration indicate adrenal insufficiency per recent guidelines, without specification of how the cosyntropin is administered (intravenously or intramuscularly). However, the peak stimulated cortisol cutoff value is based on old, fluorometric or radio-immunological methods that are known to detect significant amounts of glucocorticoids other than cortisol. For this reason, peak cortisol levels, as determined by older assays, may set higher thresholds than what might be considered necessary using a newer, more specific assay.

The widely-used old Elecsys® Cortisol Immunoassay from Roche Diagnostics (Cortisol I) is now replaced worldwide (including Johns Hopkins Hospital) by a new Elecsys® Cortisol assay from Roche Diagnostics (Cortisol II). The new Cortisol II assay employs a monoclonal as opposed to a polyclonal capturing antibody, which was used in the old Cortisol I assay. This results in greater specificity for cortisol. The new Cortisol II assay was shown to have strong correlation with cortisol levels measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) which is considered the gold standard for cortisol measurement.

Previous studies addressing the cortisol cutoff levels for the diagnosis of adrenal insufficiency with different cortisol assays have been heterogeneous in terms of the dose and route of administration of cosyntropin used, and the wide variety of subjects being tested including healthy subjects that are occasionally on oral estrogen therapy and patients with adrenal insufficiency.

Many clinical centers use intramuscular cosyntropin injections given its convenience, and as mentioned earlier, many institutions are now using the new Roche Cortisol II assay.

Investigators will conduct a study looking at healthy subjects to establish the expected range of peak cosyntropin-stimulated cortisol levels with two different cosyntropin administration modalities. The goal of this study is to compare intravenous (IV) and intramuscular (IM) administration, and to generate a normal range of post-cosyntropin serum cortisol measure with the new assay.

The two aims of the study are: (1) Compare the cortisol values at baseline, 30 minutes and 60 minutes after IV and IM cosyntropin stimulation testing in the same subjects. (2) Generate assay-specific normal ACTH stimulation test results

Detailed Description

Investigators will conduct a study looking at healthy subjects to establish the expected range of peak cosyntropin-stimulated cortisol levels in normal healthy subjects with two different cosyntropin administration modalities. The goal of this study is to compare intravenous (IV) and intramuscular (IM) administration, and to generate a normal range of post-cosyntropin serum cortisol measure with the new assay.

The two aims of the study are: (1) Compare the cortisol values at baseline, 30 minutes and 60 minutes after IV and IM cosyntropin stimulation testing in the same subjects. (2) Study the values obtained using the new Roche Cortisol II assay and establish a new reference range for cosyntropin-stimulated cortisol levels in healthy subjects for both cosyntropin administration modalities.

The widely-used old Elecsys® Cortisol Immunoassay from Roche Diagnostics (Cortisol I) is now being replaced worldwide by a new Elecsys® Cortisol assay from Roche Diagnostics (Cortisol II). The new Cortisol II assay is also a competitive immunoassay, but employs a monoclonal as opposed to a polyclonal capturing antibody, which was used in the old Cortisol I assay. This results in greater specificity for cortisol with less interference from other endogenous or exogenous glucocorticoids. The new Cortisol II assay was shown to have strong correlation with cortisol levels measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) which is considered the gold standard for cortisol measurement. It has been shown in earlier studies that Cortisol II assay generates cortisol values that are approximately 20-30% lower than the older Cortisol I immunoassay with proposed new cortisol cutoff for the diagnosis of adrenal insufficiency between 350-375 nmol/L (12.7-13.6 µg/dL).

This is a prospective study on healthy subjects. Investigators will perform two cosyntropin stimulation tests on participants on two separate visits, one using intravenous and another one using intramuscular cosyntropin (250 µg). Investigators will allow a minimum of one week and a maximum of 2 months between the two tests.

Blood samples for each of the two tests will be drawn at baseline, before cosyntropin administration, then at 30 minutes and 60 minutes after cosyntropin administration from indwelling catheter. A maximum of 5 ml of blood will be drawn at each time point. Serum will be separated, and samples will be stored at - 80o C after collection until analyzed.

All of the blood samples will be tested to measure cortisol levels using the new Roche Cortisol II assay. The Cortisol assay kits will be provided from Roche Diagnostics.

Overall study duration will be 18 months. There will be two study visits. Investigators will allow a minimum of one week and a maximum of 2 months between the two visits.

The study will include 40 healthy subjects between the ages of 18 and 65. Investigators will exclude subjects with known hypothalamic-pituitary adrenal axis or other endocrine disease, glucocorticoid use (chronic, current, or within 3 months), pregnancy or oral estrogen use. Women will be studied during the same menstrual cycle phase for each of the 2 tests. Participants will be recruited by word of mouth and adds placed within the medical school campus. Participants will provide written informed consent.

Study Statistics

1. Primary outcome variable.

1. Comparison between peak cosyntropin-stimulated cortisol levels measured using IV and IM cosyntropin administration in the same subjects

2. Establishing new reference range for expected peak cosyntropin-stimulated cortisol levels using the new Cortisol II assay for both cosyntropin administration modalities.

2. Secondary outcome variables.

3. Statistical plan including sample size justification and interim data analysis.

To test the hypothesis that the cortisol levels after IM administration of cosyntropin is slightly lower than IV administration, the investigator assume that 1) proportional analytical variability (constant CV) for both methods; 2) a difference > 50% of analytical variability is clinically meaningful (i.e., an effect size of 0.5). A sample size of 30 subjects will provide 85% power at a significance level of 5% using one-sided paired t-test. When the two time point data are analyzed together, the power will be higher.

For correlation estimation, the sample size of 30 produces a two-sided 95% confidence interval with a width < 0.153, assuming the sample correlation is >0.900.

With the proposed 40 healthy subjects, the distance of the reference range (defined as 95 percentile of the reference population) from the upper-bound of the estimated 95% confidence interval will be < 22%.

Conditions

Adrenal Insufficiency

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Intravenous and intramuscular administration

Subjects will receive intravenous and intramuscular ACTH on different days

Group Type: EXPERIMENTAL

Cosyntropin

Intervention Type: DRUG

intramuscular and intravenous administration

Interventions

Cosyntropin

intramuscular and intravenous administration

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy volunteers

Exclusion Criteria

• Know history of pituitary or adrenal disease. Current or recent use of glucocorticoids, and use of oral estrogen, pregnancy

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Johns Hopkins University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

IRB00193457

Identifier Type: -

Identifier Source: org_study_id